Sandoz has made several announcements regarding the U.S. generic antitrust class action litigation.
They have reached a settlement agreement with final payor plaintiffs, resulting in a payment of $275 million.
This payment is expected to be completed by the end of 2024.
In addition, the company has set aside $265 million to cover outstanding claims from opt-out plaintiffs and state attorneys general.
Sandoz has stated that these developments will not impact their current forecasts for 2024 or their medium-term outlook.